Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OCEAW | US
0.00
2.58%
Healthcare
Biotechnology
30/09/2023
21/10/2024
0.04
0.04
0.04
0.03
Ocean Biomedical Inc. a biopharmaceutical company focuses on discovering and developing therapeutic products in oncology fibrosis infectious diseases and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence Rhode Island. Ocean Biomedical Inc. operates as a subsidiary of Poseidon Bio LLC.
View LessLow Debt to Equity (< 0.25)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
233.6%1 month
238.3%3 months
449.1%6 months
394.4%-
-
-
-0.16
11.69
-
-
-
-
-
-
-
-
-
-
-
-
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.03
Range1M
0.03
Range3M
0.16
Rel. volume
0.77
Price X volume
1.69K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
XOMAP | XOMAP | Biotechnology | 26.24 | 0 | -0.23% | 26.27 | 121.93% |
XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock | XOMAO | Biotechnology | 25.5992 | 0 | 0.02% | 25.57 | 121.93% |
SABSW | SABSW | Biotechnology | 0.0534 | 0 | 8.54% | 0.17 | 11.58% |
Revolution Medicines Inc. Warrant | RVMDW | Biotechnology | 0.1195 | 0 | 18.32% | n/a | 5.40% |
REVBW | REVBW | Biotechnology | 0.0129 | 0 | -3.01% | n/a | 0.00% |
Rocket Pharmaceuticals Inc. Warrant | RCKTW | Biotechnology | 0.0666 | 0 | -6.06% | n/a | 0.00% |
Nutriband Inc. Warrant | NTRBW | Biotechnology | 1.15 | 0 | 9.52% | n/a | 1.72% |
NKGen Biotech Inc. Warrants | NKGNW | Biotechnology | 0.032 | 0 | 29.03% | n/a | -40.33% |
JSPRW | JSPRW | Biotechnology | 0.21 | 0 | 0.00% | n/a | 2.31% |
ICUCW | ICUCW | Biotechnology | 0.039 | 0 | 0.52% | n/a | -45.50% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
No data |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | - | 0.53 | - |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | - | 15.55 | - |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 449.06 | 72.80 | Riskier |
Debt to Equity | -0.16 | -1.23 | Expensive |
Debt to Assets | 11.69 | 0.25 | Expensive |
Market Cap | - | 3.66B | - |